◆英語タイトル：Global Plasma Protein Therapeutics Market Size study & Forecast, by Product Type (C1 esterase Inhibitors, Albumins, Immunoglobulins, Others), by Application (Hereditary Angioedema, Hemophilia, Primary Immunodeficiency Disorder, Others) and Regional Analysis, 2022-2029
	◆商品コード：BZW23MA038 ◆発行会社（リサーチ会社）：Bizwit Research & Consulting ◆発行日：2023年4月10日 ◆ページ数：約200 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東 ◆産業分野：医薬品

Global Plasma Protein Therapeutics Market is valued at approximately USD 27.45 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 7% over the forecast period 2022-2029. Plasma protein therapeutics is a biological medicine made up of plasma. It is a biological substance with a distinct chemical composition depending upon how it was produced and processed. The majority of blood is made up of plasma, contains water, salts, proteins, antibodies, and enzymes. The Plasma Protein Therapeutics market is expanding because of factors such as increasing incidence of immune deficiency disorder and surge in geriatric populations. Its prevalence has progressively increased during the last few years.

Plasma protein therapies are used in the treatment of various chronic, life-threatening, and genetic diseases. Its prevalence has progressively increased during the last few years. According to Statista, plasma demand around the world was expected to increase up to 50 million liters by 2020. Furthermore, in 2020, more than 1018.8 metric tons of albumin were consumed worldwide and projected to reach around 1125.5 metric tons by 2022. It is a global protein generated from blood plasma used for cancer diagnostics and therapies, and Morbus Wilson treatments. It is used mostly for cancer diagnostics and therapies. Another important component driving space is increasing geriatric populations. In 2022, Monaco was the country with the highest percentage of total population that was over the age of 65. Monaco has the oldest population in the world with 36 percent of Japanese over 65. Germany on the other hand has 22 percent of its population being over 65 in 2022. In addition Approximately 25% of the world’s population is under 15, while 10% is over 65. The youngest population in the world is found in Africa. Indicating the low life expectancy in many nations, 40% of people on the continent are under the age of 15 and less than 4% are over 65. Contrarily, in Europe, a greater proportion of the population is over 65 than is under 15 years old. Furthermore, in 2021 Baxter International Inc. announced the global launch of PrisMax 2. It is designed to simplify delivery of continuous renal replacement therapy and organ support plasma therapies, while providing flexibility to meet the demands of the intensive care unit . The PrisMax 2 system features the company’s TrueVue digital health portfolio, as well as the PrismaLung blood-gas exchanger that delivers extracorporeal carbon dioxide removal therapy to support acute respiratory dysfunction. However, the high cost of Plasma Protein Therapeutics stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Plasma Protein Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the space in terms of revenue, owing to the dominance of increase in healthcare expenditure. According to Statista, the Health Care segment of north America is projected to reach USD 20.77 billion in 2023 and expected to show an annual growth rate of 12.25% in between 2023 to 2027, resulting in a projected market volume of USD 32.97 billion by 2027.Furthermore, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing research and development related to plasma protein therapies in the market space.

Major market players included in this report are:
Baxter International
Biotest
CSL Behring
China Biologics
GRIFOLS, S.A.
Kedrion
Octapharma USA, Inc
Shire Plc
Takeda Pharmaceutical Company Ltd
ADMA Biologics, Inc

Recent Developments in the Market:
 In April 2020, Kedrion Biopharma collaborated with Kamada Ltd. For manufacturing, development, and distribution of a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for COVID-19 patients

Global Plasma Protein Therapeutics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product Type, Application, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product Type:
C1 esterase Inhibitors
Albumins
Immunoglobulins
Others

By Application:
Hereditary Angioedema
Hemophilia
Primary Immunodeficiency Disorder
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World